The Scleroderma Foundation Teams Up with Traitwise PDF Print E-mail
Tuesday, 16 February 2010 14:40
The Scleroderma Foundation has teamed up with Austin, TX company, Traitwise Incorporated, to launch a unique survey to poll thousands of scleroderma patients and their caregivers. Data from the survey will be shared with researchers nationally and internationally in an effort to improve understanding and treatment of scleroderma.

By gathering answers about everything from symptoms to family history of disease to quality of life - and then comparing every answer to every other answer - the survey mechanism promises to tease out previously unsuspected patterns that can lead to new diagnostics, treatments, and even a cure for this chronic autoimmune disease that afflicts approximately one in every thousand people.

"As common as it is and despite the heroic efforts of clinicians and researchers, scleroderma still isn't well understood," said Scleroderma Foundation CEO Robert Riggs. "The Traitwise survey gives us a chance to assemble and analyze more pieces of the puzzle and really move research forward."

The unique Traitwise approach to data security allows users to volunteer information without fear that the information will be shared or used to identify them. Once it's made anonymous, data will be made available to researchers through the Scleroderma Foundation. "We understand that the information we seek is sensitive and personal," said Executive Vice President Michael Simpson of Traitwise. "So we answer every user's privacy expectation with an iron-clad commitment to protect their personal information."

Source: MMD Newswire
 
More articles :

» Caution Needed When Using ACE Inhibitors in Scleroderma

Exposure to angiotensin-converting enzyme inhibitors prior to the onset of renal crisis in patients with increases the risk of death, according to 1-year findings from the prospective observational International Scleroderma Renal Crisis Survey.The...

» When Our Antibodies Turn On Us

More than 32 million Americans harbor potentially toxic proteins that can attack body tissues and lead to autoimmune diseases such as Lupus and , according to a new study. This is the first accurate estimate of the frequency of the proteins, called...

» Testing New Drugs for Early Diffuse Systemic Sclerosis

For patients with the connective tissue disease known as Systemic Sclerosis or – there are few reliable drug treatments. There has been emerging interest in the potential of a class of drugs called (TKI) to ameliorate a major feature of the...

» Patients With Scleroderma May Not Exhibit Increased Corneal Thickness

in patients with systemic sclerosis may not differ significantly from those of healthy patients, contrary to prior hypothesis, a study found."Because [] is characterized by increased deposition of and other connective tissue components in the skin...

» Silicone and Scleroderma Revisited

Silicone, a synthetic polymer considered to be a biologically inert substance, is used in a multitude of medical products, the most publicly recognized of which are breast implants. Silicone breast implants have been in use since the early 1960s for...

» Sildenafil Reduces Raynaud's Frequency in Systemic Sclerosis Patients

Researchers in Europe reported that treatment with modified-release sildenafil significantly reduced the frequency of attacks of in patients with limited cutaneous systemic sclerosis (lcSSc), also known as . The double-blind, placebo-controlled...